TNFSF10 and gastric cancer: For example, combined treatment with TRAIL and bortezomib supported robust synergistic response with heightened activation of caspases-8, -9, and -3, and reinforced Annexin V-binding cell fractions in TRAIL-resistant SNU-216 gastric cancer cells.